LL-37
Reviewed privately during consultation. Public pages do not display dosing or pricing.
Back to peptide library
Antimicrobial peptide
LL-37
Wound-healing support, immune modulation, antimicrobial-support pathways, inflammatory regulation, and advanced recovery support.
Natural human defense peptideBroad antimicrobial supportDual action mechanismImmune system support
The science
What is LL-37?
LL-37 is the only known antimicrobial peptide derived from cathelicidin in humans and is part of the innate immune system’s first-line response.
LL-37 supports broad antimicrobial-defense pathways, immune-cell signaling, inflammatory regulation, epithelial cell migration, angiogenesis, toxin-neutralizing pathways, and wound-healing biology.
IPS uses LL-37 as an advanced immune-modulating peptide only when the clinical picture supports immune resilience, antimicrobial-support pathways, tissue repair, and provider-guided monitoring.
Ideal for
- Patients whose goals match this protocol category
- Recovery plans that require clinician review
- Patients needing instructions, monitoring, and candidacy screening
- Plans integrated with rehab, nutrition, sleep, and lifestyle strategy
Available through IPS
Clinical protocol context.
IPS reviews route, timing, candidacy, contraindications, tolerance, and protocol details privately during consultation. Public pages do not list dosing or pricing.
Subcutaneous
Used only with provider direction and patient education.
Immune and tissue support
Advanced recovery use when clinically appropriate.
How it works
Mechanism and clinical use.
This page explains the core mechanisms and clinical focus areas without presenting a self-selection menu.
Direct antimicrobial action
Supports innate immune-defense pathways.
Immune modulation
Supports immune-cell recruitment and inflammatory regulation.
Wound healing
Supports angiogenesis, epithelial migration, and tissue remodeling.
Advanced protocol
Reserved for select immune and tissue-repair goals.
Clinical benefits
Why IPS considers LL-37.
Benefits depend on patient goals, health history, protocol design, adherence, and response.
Broad-spectrum defenseSupports antimicrobial-defense pathways.
Wound-healing supportSupports tissue repair and epithelial migration.
Immune system supportSupports immune-cell signaling and coordinated immune response.
Inflammatory regulationSupports inflammatory balance during recovery.
Process
How this works at IPS.
Consultation
Review goals, symptoms, medical history, medications, and current care.
Candidacy Review
Review contraindications, route, tolerance considerations, and clinical fit.
Custom Protocol
If appropriate, IPS reviews instructions, expectations, and follow-up timing.
Ongoing Care
Follow-ups evaluate tolerance, response, and next-step adjustments.
Questions
Frequently asked.
What makes LL-37 different from antibiotics?
LL-37 is not a conventional antibiotic. It is an antimicrobial peptide that belongs to the body’s innate immune-defense system.
Who is LL-37 best suited for?
Select patients needing advanced immune-resilience, antimicrobial-support pathways, wound-healing support, or tissue-repair support under medical supervision.
How is LL-37 administered?
When appropriate, IPS uses provider-guided subcutaneous protocols with patient-specific instructions.
Can LL-37 combine with other therapies?
Yes. It can integrate with wound-care strategies, SoftWave Therapy, regenerative recovery, nutrition, immune support, and conventional care when appropriate.
Contact
Discuss LL-37 with IPS.
Complete the form and IPS will follow up about consultation scheduling and next steps.
Send your details and IPS can follow up about consultation scheduling, eligibility, and next steps.
Medical noteThis educational page is not a diagnosis or treatment plan. Consultation and provider review are required.